Accessibility Menu

Neumora Therapeutics

(NASDAQ) NMRA

Current Price$1.56
Market Cap$169.44M
Since IPO (2023)-94%
5 YearN/A
1 Year+8%
1 Month-50%

Neumora Therapeutics Financials at a Glance

Market Cap

$169.44M

Revenue (TTM)

$0.00

Net Income (TTM)

-$222.39M

EPS (TTM)

-$1.33

P/E Ratio

-0.69

Dividend

$0.00

Beta (Volatility)

1.86 (High)

Price

$1.56

Volume

560,964

Open

$0.95

Previous Close

$1.56

Daily Range

$0.92 - $1.58

52-Week Range

$0.72 - $3.65

Estimated Earnings Date

Aug 6, 2026

NMRA: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neumora Therapeutics

Industry

Pharmaceuticals

Employees

96

CEO

Paul L. Berns

Headquarters

Watertown, DE 02472, US

NMRA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-149%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-1.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$169.44M

Shares Outstanding

185.28M

Volume

560.96K

Avg. Volume

1.48M

Financials (TTM)

Gross Profit

-$5.00M

Operating Income

-$241.16M

EBITDA

-$233.37M

Operating Cash Flow

-$206.44M

Capital Expenditure

$0.00

Free Cash Flow

-$206.44M

Cash & ST Invst.

$182.53M

Total Debt

$477.00K

Neumora Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$8.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$169.44M

N/A

Market Cap/Employee

$1.54M

N/A

Employees

110

N/A

Net Income

-$53.46M

+21.4%

EBITDA

-$51.57M

+23.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$147.07M

-41.0%

Total Debt

$410.00K

-56.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$119.00K

N/A

Short Term Debt

$291.00K

-69.0%

Return on Assets

-1.45%

N/A

Return on Invested Capital

-1.80%

N/A

Free Cash Flow

-$46.40M

+21.9%

Operating Cash Flow

-$46.40M

+21.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FULCFulcrum Therapeutics, Inc.
$3.46-1.42%
ADCTADC Therapeutics S.A.
$1.00-5.11%
BCYCBicycle Therapeutics plc
$4.02-3.13%
AUTLAutolus Therapeutics plc
$1.49-0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.71+0.02%
SOFISoFi Technologies
$17.71+0.03%
SNAPSnap
$5.16-0.10%
RXTRackspace Technology
$6.21+0.05%

Questions About NMRA

What is the current price of Neumora Therapeutics?

Neumora Therapeutics is trading at $1.56 per share.

What is the 52-week range for Neumora Therapeutics?

Over the past 52 weeks, Neumora Therapeutics has traded between $0.72 and $3.65.

How much debt does Neumora Therapeutics have?

As of the most recent reporting period, Neumora Therapeutics reported total debt of $53.37M.

How much cash does Neumora Therapeutics have on hand?

Neumora Therapeutics reported $147.07M in cash and cash equivalents in its most recent financial results.

What is Neumora Therapeutics’s dividend yield?

Neumora Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.